Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
What perioperative systemic therapy would you use for a patient with oligometastatic clear cell RCC with a bony metastasis at risk for fracture?
Related Questions
How do you reconcile the lack of OS benefit in the CLEAR trial comparing Lenvatinib + Pembrolizumab to Sunitinib, to the very impressive ORR and mPFS benefit seen?
Do you need renal biopsy before SBRT for RCC suspicious cancer?
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
Do you recommend any alternative schedule for cabozantinib to make treatment compliance easier for patients with metastatic renal cell carcinoma?
What adjuvant therapy, if any, is best for mucinous tubular and spindle cell carcinoma of the kidney?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
How are you utilizing subcutaneous Nivolumab in genitourinary cancers?
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
What is your preferred regimen for a patient with clear cell RCC, progression after an IO+IO regimen, with a chronic non-healing wound?
What are your top takeaways from ASCO GU 2025?
